Taking people in GreecePhase 1
Tests cevostamab injections in adults with relapsed or refractory multiple myeloma
Tests cevostamab injected under the skin in adults with myeloma that returned.
Key facts
- Who runs it
- Genentech Inc.
- Where
- Athens, GreeceSee the 2 sitesAlso in 2 other countries, 4 sites
- Registry title
- A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 45 people, planned
- Started
- 8 Dec 2021
- Expected to end
- 30 Jun 2028
- Type of study
- Interventional
- Record updated
- 24 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose multiple myeloma has come back or has not responded to earlier treatment.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Multiple myeloma that has relapsed or is refractory (it came back or did not respond to treatment).
Where in Greece
Also in 2 other countries, 4 sites
- Alexandra HospitalAthens, GreeceTaking people
- Evangelismos S AAthens, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests cevostamab injections in adults with relapsed or refractory multiple myelomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 24 August 2026